Epidemiology


  • Age > 50 (most significant risk factor due to immunosenescence).
  • Immunocompromised (IC) states (HIV, malignancy, transplant, immunosuppressive meds, radiation therapy).
  • Physical trauma or severe psychological stress.

Etiology


Pathophysiology


Clinical features


  • Prodrome:
    • Burning, tingling, itching, or lancinating pain in a dermatomal distribution.
    • Allodynia: a sensation of pain triggered by a stimulus that is not ordinarily considered painful. c
    • Precedes the rash by 48-72 hours.
    • Fever, malaise, headache may occur.
  • Eruptive phase:
    • Unilateral, dermatomal erythematous macules/papules.
    • Progresses to grouped vesicles on an erythematous base (“dewdrops on a rose petal” appearance).
    • Does not cross the midline.
    • Most common in thoracic and trigeminal dermatomes.
    • Vesicles pustulate, ulcerate, and crust over within 7-10 days (no longer infectious once fully crusted).

Subtypes and variants


Herpes zoster ophthalmicus (HZO)

  • Definition: reactivation of VZV in the ophthalmic division of the trigeminal nerve
  • Clinical features
    • Fever and skin symptoms as in shingles
    • Herpes zoster conjunctivitis
    • Herpes zoster keratitis
    • Involvement of the ophthalmic nerve: reduced corneal sensitivity with severe pain in the innervated regions (forehead, bridge and tip of the nose)
    • Involvement of the nasociliary nerve:
      • Possible severe intraocular infection (uveitis, iritis, conjunctivitis, keratitis, and optic neuritis)
      • Positive Hutchinson sign of the nose: a vesicular rash on the nasal alae

Herpes zoster oticus

  • Definition: reactivation of VZV in the geniculate ganglion, affecting the seventh (facial) and eighth (vestibulocochlear) cranial nerves (also known as Ramsay Hunt syndrome)
  • Clinical features
    • Classic Triad:
      1. Severe otalgia (deep, burning, paroxysmal ear pain).
      2. Vesicular rash: Erythematous vesicles/crusts on the pinna, external auditory canal (EAC), tympanic membrane (TM), or anterior 2/3 of the tongue / soft palate. c
      3. Peripheral facial nerve (CN VII) palsy: Ipsilateral upper AND lower facial weakness (inability to furrow forehead, close eye, or smile; loss of nasolabial fold). c
    • CN VIII Involvement (frequent due to proximity in the internal auditory canal):
      • Sensorineural hearing loss (SNHL).
      • Tinnitus.
      • Vertigo, nystagmus, nausea, and vomiting.
    • Other Associated Features:
      • Altered taste (anterior 2/3 of tongue via chorda tympani).
      • Decreased lacrimation (dry eye) or salivation.
      • Hyperacusis (stapedius muscle paralysis).

Diagnostics


Positive Hutchinson sign of the nose: a vesicular rash on the nasal alae

Treatment


Complications


Postherpetic neuralgia

  • Definition: chronic neuropathic pain persisting for at least three months in the area previously affected by the rash
    • Postherpetic neuralgia only happens in VZV, not other herpesviruses
  • Epidemiology
    • Most common complication (occurs in 10–20% of overall herpes zoster cases)
    • Strong association with age
  • Risk factors
    • Age > 50 years
    • Severe infection (severe pain or rash)
  • Clinical features
    • Pain (including allodynia, paresthesias, dysesthesias) in the same dermatome as the rash
    • Duration of symptoms > 3 months but can persist for years
  • Treatment
    • One of the following tricyclic antidepressants:
      • Reduces serotonin and norepinephrine at the same time
      • Amitriptyline
      • Nortriptyline
      • Relative contraindications: patients with heart disease, epilepsy, or glaucoma
      • Should be used with caution in elderly patients
    • One of the following anticonvulsants:
      • Pregabalin
      • Gabapentin
    • Topical treatments
      • Capsaicin patch or cream